Acutaas Chemicals (ACUTAAS) Q1 26/27 earnings summary

Executive summary

• Revenue from operations for Q1 FY27 grew 59.1% year-over-year to ₹3,297 million, reflecting strong business momentum and operational agility.

• EBITDA for Q1 FY27 increased by 122.1% year-over-year to ₹1,131 million, with EBITDA margin improving to 34.3%.

• PAT for Q1 FY27 rose 70.4% year-over-year to ₹750 million, with PAT margin at 22.7%.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved by the Board and reviewed by statutory auditors with no modifications.

• Recognized as a Great Place to Work and received Responsible Care certification, highlighting commitment to culture and sustainability.

Financial highlights

• Consolidated revenue from operations for Q1 FY27 was ₹32,967.48 lakhs, up from ₹20,723.72 lakhs in Q1 FY26 and down from ₹43,275.05 lakhs in Q4 FY26.

• Consolidated net profit for Q1 FY27 was ₹7,426.01 lakhs, compared to ₹4,429.34 lakhs in Q1 FY26 and ₹13,176.08 lakhs in Q4 FY26.

• Gross profit for Q1 FY27 was ₹1,909 million, up 73.0% year-over-year, with gross margin at 57.9%.

• Sequentially, revenue declined 23.8% and EBITDA dropped 38.4% from Q4 FY26.

• FY20-25 revenue CAGR was 31.0%, with FY26 revenue at ₹13,394 million.

Outlook and guidance

• Management remains confident of delivering 25% revenue growth for the full year with stable margins.

• Management does not expect any material impact from recent regulatory inspections on the company’s financial position, operations, or cash flows.